Genentech sues Biogen for debt over blockbuster MS drug

Published Date: 08 Mar 2023

Roche's Genentech Inc sued Biogen MA Inc in federal court in San Francisco, alleging that Biogen owed additional patent royalties from worldwide sales of its blockbuster multiple sclerosis and Crohn's disease drug, Tysabri.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Doxorubicin-Trabectedin Strategy Boosts Survival in Challenging Sarcoma

2.

Living in a more pedestrian-friendly area may reduce the risk of cancer and obesity-related diseases.

3.

Patients value communication skills from cancer surgeons across six key areas, according to research

4.

FDA Approves Treosulfan as Part of AML/MDS Conditioning Regimen

5.

The Benefits of Exercise for Substance Use Disorders.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot